Patent Grant
6858719
The field of the invention is generation of binding proteins.
The ability to produce monoclonal antibodies has revolutionized diagnostic and therapeutic medicine. Monoclonal antibodies are typically produced by immortalization of antibody-producing mouse lymphocytes thus ensuring an endless supply of cells which produce mouse antibodies. However, for many human applications, it is desirable to produce human antibodies. For example, it is preferable that antibodies which are administered to humans for either diagnostic or therapeutic purposes are human antibodies since administration of human antibodies to a human circumvents potential immune reactions to the administered antibody, which reactions may negate the purpose for which the antibody was administered.
In addition, there exists certain situations where, for diagnostic purposes, it is essential that human antibodies be used because other animals are unable to make antibodies against the antigen to be detected in the diagnostic method. For example, in order to determine the Rh phenotype of human red blood cells (RBCs), human sera that contains anti-Rh antibody must be used since other animals cannot make an antibody capable of detecting the human Rh antigen.
The production of human antibodies in vitro by immortalizing human B lymphocytes using Epstein Barr virus (EBV)-mediated transformation or cell fusion has been fraught with technical difficulties due to the relatively low efficiency of both EBV-induced transformation and cell fusion when compared with the murine system. To overcome these problems, processes have been developed for the production of human antibodies using M13 bacteriophage display (Burton et al., 1994, Adv. Immunol. 57:191-280). Essentially, a cDNA library is generated from mRNA obtained from a population of antibody-producing cells. The mRNA encodes rearranged immunoglobulin (Ig) genes and thus, the cDNA encodes the same. Amplified cDNA is cloned into M13 expression vectors creating a library of phage which express human Fab fragments on their surface. Phage which display the antibody of interest are selected by antigen binding and are propagated in bacteria to produce soluble human Fab Ig. Thus, in contrast to conventional monoclonal antibody synthesis, this procedure immortalizes DNA encoding human Ig rather than cells which express human Ig.
There are several difficulties associated with the generation of antibodies using bacteriophage. For example, many proteins cannot be purified in a non-denatured state, in that purification procedures necessarily involve solubilization of protein which may render some proteins permanently denatured with concomitant destruction of antigenic sites present thereon. Such proteins thus cannot be bound to a solid phase and therefore cannot be used to pan for phage bearing antibodies which bind to them. An example of such a protein is the human Rh antigen.
To solve the problem, a method was developed wherein intact RBCs were used as the panning antigen (Siègel et al., 1994, Blood 83:2334-2344). However, it was discovered that since phage are inherently “sticky” and RBCs express a multitude of antigens on the cell surface, a sufficient amount of phage which do not express the appropriate antibody on the surface also adhere to the RBCs, thus rendering the method impractical for isolation of phage which express antibody of desired specificity.
De Kruif et al. (1995, Proc. Natl. Acad. Sci. USA 92:3938-3942) disclose a method of isolating phage encoding antibodies, wherein antibody-expressing phage are incubated with a mixture of antigen-expressing cells and cells which do not express antigen. The antibody-expressing phage bind to the antigen-expressing cells. Following binding with phage, a fluorescently labeled antibody is added specifically to the antigen-expressing cells, which cells are removed from the mixture having antibody-expressing phage bound thereto. The isolation of fluorescently labeled cells is accomplished using the technique of fluorescently-activated cell sorting (FACS), an expensive and time-consuming procedure.
There remains a need for a method of isolating recombinant proteins, preferably antibodies, which is rapid and economical, and which will provide a vast array of protein-binding proteins useful for diagnostic and therapeutic applications in humans.
The invention relates to an isolated protein having an amino acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181. In one embodiment, the isolated protein is an antigen-binding protein. In one aspect, the antigen is human Rh(D) protein. In another embodiment, the binding protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181. In one aspect, the binding protein is an antibody. In another aspect, the said antibody comprises a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-28 and 139-153. In still another aspect, the antibody comprises a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-69 and 154-181. In yet another aspect, the antibody comprises a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-28 and 139-153 and a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-69 and 154-181.
In another embodiment of the isolated binding protein, the binding protein is an antibody fusion protein.
In another embodiment of the isolated protein, the protein is substantially purified.
The invention also includes an isolated DNA encoding the isolated protein of the invention. In one embodiment, the isolated DNA has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224. In another embodiment, the DNA is substantially purified.
The invention also includes an isolated DNA encoding a protein obtained by generating a synthetic DNA library in a virus vector expressing said protein; adding a magnetic label to cells expressing said antigen-bearing moiety; incubating virus expressing said protein with said magnetically labeled cells in the presence of an excess of non-labeled cells which do not express said antigen-bearing moiety to form a mixture, wherein said virus binds to said magnetically labeled cells; isolating virus bound cells from said mixture and obtaining DNA encoding said protein therefrom. In one embodiment, the DNA has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.
The invention further includes a substantially pure protein obtained by generating a synthetic DNA library in a virus vector expressing said protein; adding a magnetic label to cells expressing said antigen-bearing moiety; incubating virus expressing said protein with said magnetically labeled cells in the presence of an excess of non-labeled cells which do not express said antigen-bearing moiety to form a mixture, wherein said virus binds to said magnetically labeled cells; isolating virus bound cells from said mixture and isolating said protein therefrom. In one embodiment, the protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181.
The invention also includes a substantially pure preparation of a protein obtained by expressing said protein from DNA encoding said protein, wherein said DNA is obtained by generating a synthetic DNA library in a virus vector expressing said protein; adding a magnetic label to cells expressing said antigen-bearing moiety; incubating virus expressing said protein with said magnetically labeled cells in the presence of an excess of non-labeled cells which do not express said antigen-bearing moiety to form a mixture, wherein said virus binds to said magnetically labeled cells; isolating virus bound cells from said mixture and obtaining DNA encoding said protein therefrom. In one embodiment, the protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181.
The invention further relates to a method of isolating a DNA encoding a multi-subunit protein which binds to an antigen-bearing moiety. This method comprises
The invention also relates to a method of isolating a multi-subunit protein which binds to an antigen-bearing moiety. This method comprises
According to the present invention, there is provided a novel method of isolating DNA encoding a protein and the protein encoded thereby, wherein the protein is preferably an antibody, which protein is capable of specifically binding to an antigen-bearing moiety.
As exemplified herein but not limited thereto, the method comprises generating bacteriophage which encode human antibodies. Specifically in the present invention, anti-Rh(D) RBC Fab/phage antibodies encoded by an M13 filamentous phage library are obtained. The library is generated from antibody-producing cells obtained from a hyperimmunized donor by first obtaining cDNA derived from mRNA expressed in the antibody-producing cells. Ig encoding fragments of the cDNA are obtained using the polymerase chain reaction (PCR) and primers specific for such fragments of DNA. Ig-specific DNA so obtained is cloned into a bacteriophage. Bacteriophage encoding the Ig fragments are panned against a mixture of antigen-positive, biotinylated RBC-target cells pre-coated with streptavidin-conjugated magnetic microbeads and excess non-labeled RBCs. Bacteriophage which express antibodies on the phage surface, which antibodies are specific for the target cell antigen, bind to the labeled cells. These phage are separated from phage which are bound to non-labeled cells and from phage which are not bound to the cells using a magnetic column. Phage so separated encode and display antibody specific for antigens on the target cells.
To generate a phage antibody library, a cDNA library is first obtained from mRNA which is isolated from cells which express the desired protein to be expressed on the phage surface, e.g., the desired antibody. cDNA copies of the mRNA are produced using reverse transcriptase. cDNA which specifies Ig fragments are obtained by PCR and the resulting DNA is cloned into a suitable bacteriophage vector to generate a bacteriophage DNA library comprising DNA specifying Ig genes. The procedures for making a bacteriophage library comprising heterologous DNA are well known in the art and are described, for example, in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y.).
A bacteriophage library may also be obtained using cDNA rather than PCR-amplified Ig encoding fragments of cDNA. Generation of a cDNA library is useful for the isolation of proteins which are not antibodies, such as ligands and the like.
Bacteriophage which encode the desired protein, e.g., an antibody, may be engineered such that the protein is displayed on the surface thereof in such a manner that it is available for binding to its corresponding binding protein, e.g., the antigen against which the antibody is directed. Thus, when bacteriophage which express a specific antibody are incubated in the presence of a cell which expresses the corresponding antigen, the bacteriophage will bind to the cell. Bacteriophage which do not express the antibody will not bind to the cell.
For panning of bacteriophage, i.e., selection of phage which express the desired antibody, cells which express the corresponding antigen are labeled with a detectable label such as biotin. Streptavidin-conjugated magnetic beads are then added to the cells. The cells are mixed with an excess of non-labeled cells which do not express the antigen. This cell mixture is then incubated with the phage library, wherein phage which express the antibody bind to cells expressing the antigen. The presence of the excess non-labeled cells in the mixture serves as a means of removing bacteriophage which do not express the antibody but which might otherwise bind to antigen-expressing cells non-specifically. The details of the experimental procedures for practicing the present invention are provided herein in the experimental detail section.
Antigen-expressing cells having antibody-expressing phage bound thereto are magnetically removed from the mixture. One example of magnetic removal involves pouring the mixture of magnetic and non-magnetic cells into a column in the selective presence or absence of a magnetic field surrounding the column. Alternatively, magnetic cells may be separated from non-magnetic cells in solution by simply holding a magnet against the side of a test tube and attracting the cells to the inner wall and then carefully removing the non-magnetic cells from the solution.
Thus, the method of the invention involves a procedure for enriching a population of recombinant phage for those expressing specific phage-displayed ligands derived from natural or synthetic phage DNA libraries by simultaneously performing negative and positive selection against a mixture of magnetically-labeled receptor-positive particles (i.e., cells) and non-labeled receptor-negative particles.
The terms “bacteriophage” and “phage” are used interchangeably herein and refer to viruses which infect bacteria. By the use of the terms “bacteriophage library” or “phage library” as used herein, is meant a population of bacterial viruses comprising heterologous DNA, i.e., DNA which is not naturally encoded by the bacterial virus.
The term “virus vector” includes a virus into which heterologous DNA has been inserted. The virus vector may be a bacteriophage or may be a eukaryotic virus.
By the term “target cell” as used herein, is meant a cell which expresses an antigen against which the desired antibody is sought.
By the term “panning” or “panned” as used herein, is meant the process of selecting phage which encode the desired antibody.
By the term “Fab/phage” as used herein, is meant a phage particle which expresses the Fab portion of an antibody.
By the term “scFv/phage” are used herein, is meant a phage particle which expresses the Fv portion of an antibody as a single chain.
By “excess non-labeled cells” is meant an amount of non-labeled cells which exceeds the number of labeled cells. Preferably, the ratio of labeled cells to non-labeled cells is about 1:2. More preferably, the ratio of labeled cells to non-labeled cells is greater than about 1:4. Even more preferably, the ratio of labeled cells to non-labeled cells is greater than about 1:10.
While the method of the invention as exemplified herein describes the generation of phage which encode the Fab portion of an antibody molecule, the method should not be construed to be limited solely to the generation of phage encoding Fab antibodies. Rather, phage which encode single chain antibodies (scFV/phage antibody libraries) are also included in the invention. Fab molecules comprise the entire Ig light chain, that is, they comprise both the variable and constant region of the light chain, but include only the variable region and first constant region domain (CH1) of the heavy chain. Single chain antibody molecules comprise a single chain of protein comprising the Ig Fv fragment. An Ig Fv fragment includes only the variable regions of the heavy and light chains of the antibody, having no constant region contained therein. Phage libraries comprising scFV DNA may be generated following the procedures described in Marks et al., 1991, J. Mol. Biol. 222:581-597. Panning of phage so generated for the isolation of a desired antibody is conducted as described herein for phage libraries comprising Fab DNA.
The invention should also be construed to include synthetic phage display libraries in which the heavy and light chain variable regions may be synthesized such that they include nearly all possible specificities. Therefore, antibody-displaying libraries can be “natural” or “synthetic” (Barbas, 1995, Nature Medicine 1:837-839; de Kruif et al. 1995, J. Mol. Biol. 248:97-105). Antibody-displaying libraries comprising “natural” antibodies are generated as described in the experimental example section. Antibody-displaying libraries comprising “synthetic” antibodies are generated following the procedure described in Barbas (1995, supra) and the references cited therein.
The method of the invention should be further construed to include generation of phage display libraries comprising phage other than M13 as exemplified herein. Other bacteriophage, such as lambda phage, may also be useful in the method of the invention. Lambda phage display libraries have been generated which display peptides encoded by heterologous DNA on their surface (Sternberg et al., 1995, Proc. Natl. Acad. Sci. USA 92:1609-1613). Moreover, it is contemplated that the method of the invention may be extended to include viruses other than bacteriophage, such as eukaryotic viruses. In fact, eukaryotic viruses may be generated which encode genes suitable for delivery to a mammal and which encode and display an antibody capable of targeting a specific cell type or tissue into which the gene is to be delivered. For example, retroviral vectors have been generated which display functional antibody fragments (Russell et al., 1993, Nucl. Acids Res. 21:1081-1085).
The red blood cell antibodies to which antibodies may be generated include, but are not limited to, Rh antigens, including Rh(D), Rh(C), Rh(c), Rh(E), Rh(e), and other non-Rh antigens, including red blood cell antigens in the Kell, Duffy, Lutheran and Kidd blood groups.
Thus, the method of the invention is not limited solely to the isolation of DNA encoding anti-Rh(D) antibodies, but rather may be used for the isolation of DNA encoding antibodies directed against any RBC antigen or other cell antigen, such as, but not limited to, tumor-specific antigen, bacterial antigens, and the like. The method of the invention is also useful for typing platelets by generating phage antibodies specific for a number of clinically important platelet antigens, notably, P1A1/P1A2, Baka/Bakb, PenA/PenB, and the like.
The invention is further useful for typing donor white blood cells for HLA antigens for the purposes of matching donors and recipients for potential transplant matching in the case of both solid (for example, kidney, heart, liver, lung) and non-solid (for example, bone marrow) organ or tissue transplanting.
To detect binding of phage expressing antibody directed against one of these non-red blood cell antigens, the non-red blood cells may be agglutinated or trapped following the procedures described herein for agglutination or trapping of red blood cells. Prior to agglutination or trapping, the cells may be rendered “visible” by staining or other labeling technique in order that agglutination or trapping is apparent to the naked eye or scanner.
The method of the invention is most useful for the generation of a protein which binds to an antigen-bearing moiety, where the antigen-bearing moiety is not easily purified in soluble form. Thus, the antigen-bearing moiety includes antigens which are associated with other structures, usually membranes in the cell such as cell membranes or cell organelle membranes.
In accordance with the present invention, the antigen-bearing moiety may be a protein, a lipid, a carbohydrate or a nucleic acid, or it may be a complex of at least two of a protein, a lipid, a carbohydrate and a nucleic acid, it being appreciated that many antigen-bearing moieties in cells are not comprised of one of these components alone. Preferably, the antigen-bearing moiety is a membrane bound protein, such as an antigen or a receptor protein. However, when the antigen-bearing moiety is a carbohydrate, it may be a carbohydrate expressed on a glycolipid, for example, a P blood group antigen or other antigen.
By the term “antigen-bearing moiety” as used herein, is meant a molecule to which an antibody binds.
By the term “antigen-binding protein” as used herein, is meant a polypeptide molecule, such a an antibody, a fragment thereof or an antibody fusion protein, which is capable of specifically binding to another molecule.
By the term “antibody fusion protein” as used herein, is meant a polypeptide molecule having an amino acid sequence which comprises the amino acid sequence of a portion of an antigen-binding protein. The portion of the antigen-binding protein may, for example, be an entire antibody or a fragment thereof.
The method of the invention is also useful for the generation of autoimmune antibodies such as those involved in autoimmune hemolytic anemia (AIHA) (Siegel et al., 1994, Structural analysis of red cell autoantibodies, Garratty (ed.) Immunobiology of Transfusion Medicine, Dekker, New York, N.Y.). Autoimmune antibodies that are directed against cell antigens which are cell surface membrane associated or cell organelle membrane associated may be isolated using the technology described herein. Autoimmune diseases and their associated antigens to which antibodies may be isolated include, but are not limited to the following: Myasthenia gravis (acetylcholine receptor; neurons), chronic inflammatory demyelinating polyneuropathy (myelin; neurons), autoimmune thyroid disease (thyroid stimulating hormone receptor; thyroid cells), primary biliary cirrhosis (mitochondrial autoantigens; liver mitochondria), idiopathic thrombocytopenic purpura (platelet membrane integrins; platelets), pemphigus vulgaris (epidermal antigens; epidermis), and Goodpasture's syndrome (basement membrane antigens; kidney or lung cells).
In fact, the method of the invention is useful for the isolation of DNA clones encoding any antibody directed against an antigen expressed on a cell, which cell can be labeled with a magnetic label and which cell can be obtained in sufficient quantities in an non-labeled form so as to provide an excess of non-labeled cells as required in the assay.
Further, the method of the invention is not limited to the isolation of DNA encoding antibodies but rather may also be used for the isolation of DNA encoding other peptides or proteins having specificity for cell proteins, such as, for example, but not limited to, ligands which bind cell receptor proteins, peptide hormones, and the like.
The invention should also not be construed as being limited to the use of biotin as the cell-labeling agent. Other labels may be used provided their addition to a cell does not disturb the structural integrity of any surface proteins expressed thereon and provided such labels permit the addition of a paramagnetic microbead or other magnetic substance thereto. Other such labels include, but are not limited to, cell surface proteins or carbohydrates which can be directly derivitized with magnetic beads that possess activated amine, carboxyl, or thiol groups. In addition, dyes such as fluorescein or rhodamine may also be covalently attached to cells in a manner similar to biotin and magnetic beads coated with anti-dye antibodies may be attached thereto.
The invention also includes a screening method which may be used to isolate a DNA encoding a multi-subunit protein which binds to an antigen-bearing moiety or, alternately, to isolate the multi-subunit protein itself. The multi-subunit protein may, for example, be an antibody or another immunoglobulin. It is well known that antibodies and other immunoglobulins comprise multiple subunits, often designated heavy and light chains.
According to this screening method, a phage display library is generated, either as described herein or using other generally known or hereafter-developed methods. The library comprises a plurality of virus vectors, including a first virus vector which comprises a first heterologous DNA encoding a subunit of the protein. The first virus vector expresses the subunit on its surface, either by itself or in association with one or more other subunits of the protein. The library also comprises a second virus vector which comprises a second heterologous DNA encoding a different subunit of the protein. The second virus vector expresses the different subunit on its surface, either by itself or in association with one or more other subunits of the protein. A magnetic label is added to cells bearing the antigen-bearing moiety on their surface, and the labeled cells are incubated with the phage display library in the presence of an excess of non-labeled cells which do not express the antigen-bearing moiety. The first and second virus vectors bind to the magnetically labeled cells, owing to interaction(s) between the antigen and the subunits of the protein expressed on the surface of the vectors.
After incubating the phage display library with the mixture of cells, magnetically labeled cells are isolated from the mixture. First and second virus vectors bound to the magnetically labeled cells are thereby also isolated from the mixture. The virus vectors are separated from the magnetically labeled cells (e.g. by culturing the cells in a manner in which the virus vectors are produced in the culture supernatant), and heterologous DNA is obtained from virus vectors that adhered to the magnetically labeled cells. The DNA may optionally be purified at this stage. DNA isolated from the virus vectors that adhered to the magnetically labeled cells includes the first heterologous DNA and the second heterologous DNA.
At least the portion of the first heterologous DNA encoding the subunit is ligated to at least the portion of the second heterologous DNA encoding the different subunit to form a hybrid heterologous DNA. For this purpose, it is advantageous that the virus vector be constructed in such a way that the portion of the first heterologous DNA encoding the subunit, the portion of the second heterologous DNA encoding the different subunit, or both, are flanked or surrounded by defined restriction endonuclease cleavage sites. In such constructs, the portion of the first heterologous DNA encoding the subunit may be removed, for example, by treating the first heterologous DNA with restriction endonucleases which specifically cleave the specific sites. This portion may then be ligated, for example either directly or after ligating a linker DNA thereto, to all or a portion of the second heterologous DNA to generate the hybrid heterologous DNA.
The hybrid heterologous DNA is then used to generate a hybrid virus vector comprising the hybrid heterologous DNA. The hybrid virus vector expresses the subunit and the different subunit of the protein on its surface. For example, if the first heterologous DNA encodes an antibody light chain and the second heterologous DNA encodes an antibody heavy chain, then the hybrid virus vector may express an antibody comprising equal numbers of heavy and light chains on its surface.
The hybrid virus vector is then incubated with the mixture of magnetically labeled cells having the antigen-bearing moiety on their surface and non-magnetically labeled cells which do not have the antigen-bearing moiety on their surface. Owing to interactions between the antigen and the subunits of the protein expressed on the surface of the hybrid virus vector, the hybrid virus vector binds with the magnetically labeled cells, and may therefore be isolated from the mixture of cells by isolating magnetically labeled cells from the mixture.
As described herein, hybrid virus vector particles are isolated from the magnetically labeled cells. The isolated hybrid virus vectors may be used as a source for obtaining either the multi-subunit protein or the hybrid heterologous DNA (which encodes the subunits of the protein), using standard methods.
The invention includes proteins and DNA encoding the same which are generated using the methods described herein. To isolate DNA encoding an antibody, for example, DNA is extracted from antibody expressing phage obtained according to the methods of the invention. Such extraction techniques are well known in the art and are described, for example, in Sambrook et al. (supra).
The invention includes a number of isolated or substantially purified DNAs encoding antigen-binding proteins, such as Rh(D)-binding proteins. For example, a DNA having a nucleotide sequence comprising at least one of SEQ ID NOs: 70-138 and 182-224, as described herein, is included. The isolated or substantially purified nucleic acid may have a nucleotide sequence selected from the group consisting of SEQ ID NOs: 70-138 and 182-224.
An “isolated DNA”, as used herein, refers to a DNA sequence, segment, or fragment which has been purified from the sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in a genome in which it naturally occurs. The term also applies to DNA which has been substantially purified from other components which naturally accompany the DNA, e.g., RNA or DNA or proteins which naturally accompany it in the cell.
The invention also includes a number of isolated or substantially purified proteins, such as Rh(D)-binding proteins. For example, a protein having an amino acid sequence comprising at least one of SEQ ID NOs: 1-69 and 139-181, as described herein, is included. The isolated or substantially purified protein may have an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-69 and 139-181. The protein may be an antigen-binding protein, such as an antibody which comprises a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-28 and 139-153, a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs 29-69 and 154-181, or both. The protein may also be, for example, an antibody fusion protein.
An “isolated protein” as used herein, means a protein or polypeptide which has been separated from components which naturally accompany it in a cell. Typically, a protein or polypeptide is isolated when at least 10%, more preferably at least 20%, more preferably at least 50% of the total material (by volume, by wet or dry weight, or by mole percent or mole fraction) in a sample is the protein or polypeptide of interest.
The invention should also be construed to include DNAs which are substantially homologous to the DNA isolated according to the method of the invention. Preferably, DNA which is substantially homologous is about 50% homologous, more preferably about 70% homologous, even more preferably about 80% homologous and most preferably about 90% homologous to DNA obtained using the method of the invention.
“Homologous” as used herein, refers to the subunit sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two compound sequences are homologous then the two sequences are 50% homologous, if 90% of the positions, e.g., 9 of 10, are matched or homologous, the two sequences share 90% homology. By way of example, the DNA sequences 3′ ATTGCC 5′ and 3′ TATGCG 5′ share 50% homology.
To obtain a substantially pure preparation of a protein comprising, for example, an antibody, generated using the methods of the invention, the protein may be extracted from the surface of the phage on which it is expressed. The procedures for such extraction are well known to those in the art of protein purification. Alternatively, a substantially pure preparation of a protein comprising, for example, an antibody, may be obtained by cloning an isolated DNA encoding the antibody into an expression vector and expressing the protein therefrom. Protein so expressed may be obtained using ordinary protein purification procedures well known in the art.
As used herein, the term “substantially pure” describes a compound, e.g., a protein or polypeptide which has been separated from components which naturally accompany it. Typically, a compound is substantially pure when at least 10%, more preferably at least 20%, more preferably at least 50%, more preferably at least 60%, more preferably at least 75%, more preferably at least 90%, and most preferably at least 99% of the total material (by volume, by wet or dry weight, or by mole percent or mole fraction) in a sample is the compound of interest. Purity can be measured by any appropriate method, e.g., in the case of polypeptides by column chromatography, gel electrophoresis or HPLC analysis. A compound, e.g., a protein, is also substantially purified when it is essentially free of naturally associated components or when it is separated from the native contaminants which accompany it in its natural state.
As used herein, amino acids are represented by the fill name thereof, by the three letter code corresponding thereto, or by the one-letter code corresponding thereto, as indicated in the following table:
The present invention also provides for analogs of proteins or peptides obtained according to the methods of the invention. Analogs can differ from naturally occurring proteins or peptides by conservative amino acid sequence differences or by modifications which do not affect sequence, or by both.
For example, conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function. Conservative amino acid substitutions typically include substitutions within the following groups:
Also included in the invention are polypeptides which have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to optimize solubility properties. Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids, e.g., D-amino acids or non-naturally occurring synthetic amino acids. The peptides of the invention are not limited to products of any of the specific exemplary processes listed herein.
In addition to substantially full length polypeptides, the present invention provides for active fragments of the polypeptides. A specific polypeptide is considered to be active if it binds to an antigen-bearing moiety, for example, if a fragment of an antibody binds to its corresponding antigen in the same manner as the full length protein.
As used herein, the term “fragment,” as applied to a polypeptide, will ordinarily be at least about fifty contiguous amino acids, typically at least about one hundred contiguous amino acids, more typically at least about two hundred continuous amino acids and usually at least about three hundred contiguous amino acids in length.
The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
The experiments described in this Example provide procedures and results for the isolation and production of anti-Rh(D) red blood cell antibodies using Fab/phage display.
A method is described in
The cell-surface selection method of the present invention is readily adaptable for use in other systems, such as for the identification of putative tumor-specific antigens, and provides a rapid (less than one month), high yield approach for isolating self-replicative antibody reagents directed at novel or conformationally-dependent cell-surface epitopes.
Creation of Fab/phage Display Libraries
Separate γ1κ and γ1λ phage libraries were constructed from 2×107 mononuclear cells derived from the peripheral blood from an Rh(D)-negative individual previously hyperimmunized with Rh(D)-positive red blood cells (RBCs). The phagemid vector pComb3 (Barbas, 1991, Proc. Natl. Acad. Sci. USA 88:7978-7982) was used to create the libraries utilizing previously published methods (Barbas et al., 1991, Combinatorial immunoglobulin libraries on the surface of phage (Phabs): Rapid selection of antigen-specific Fabs. Methods: A Companion to Methods in Enzymology 2:119-124; Siegel et al., 1994, Blood 83:2334-2344).
Briefly, cDNA was prepared from the mRNA of the donor cells and heavy chain and light chain immunoglobulin (Ig) cDNA segments were amplified using the polymerase chain reaction (PCR) and the battery of human Ig primers described by Kang et al. (1991, “Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs. Methods: A Companion to Methods” in Enzymology 2:111-118) supplemented by those of Silverman et al. (1995, J. Clin. Invest. 96:417-426). The heavy and light chain PCR products were cloned into pComb3 and electroporated into E. coli. Upon co-infection with VCSM13 helper phage (Stratagene, La Jolla, Calif.), Ig DNA was packaged into filamentous phage particles which express human Fab molecules fused to the gene III bacteriophage coat protein.
Panning Fab phage display libraries for anti-Rh(D) clones
Rh(D)-positive RBCs were cell-surfaced biotinylated by incubating cells at a hematocrit of 10% with 500 μg/ml sulfo-NHS-LC-biotin (Pierce Chemical, Rockford, Ill.) for 40 minutes at room temperature (RT). Following 5 washes with phosphate-buffered saline (PBS), 8×106 biotinylated Rh(D)-positive RBCs were incubated with 10 μl of streptavidin-coated paramagnetic microbeads (MACS Streptavidin Microbeads, Mitenyi Biotec, Sunnyvale, Calif.) for 1 hour at RT in a total volume of 100 μl PBS. Non-reacted beads were removed by washing and then the magnetic bead-coated, Rh(D)-positive RBCs were mixed with a 10-fold excess (8×107) of the Rh(D)-negative (unmodified) RBCs and ˜3×1011 colony-forming units (cfu) of either the γ1κ and γ1λ Fab/phage libraries (prepared as described above) in a final volume of 40 μl PBS containing 2% non-fat dry milk (MPBS, Carnation, Nestle Food Products, Glendale, Calif.).
Following a 2 hour incubation at 37° C., the RBC/phage suspension was loaded at a flow rate of 10 μl/minute onto a MiniMACS magnetic type MS column (Mitenyi Biotec, Sunnyvale, Calif.) that was pre-equilibrated with 2% MPBS. This loading step was performed without a magnetic field around the column so as to prevent magnetic bead-coated RBCs from instantly adhering to the very top of the column, clogging it, and causing the trapping of Rh(D)negative non-biotinylated RBCs. Loading the RBC/phage incubation mixture in the absence of a magnetic field causes the antigen-negative and antigen-positive RBCs to distribute evenly throughout the column without running off since the excluded volume of the column is slightly greater than 40 μl. Once loaded, the column was placed in a magnetic field (MiniMACS magnetic separation unit, Mitenyi Biotec, Sunnyvale, Calif.) for 2 minutes to allow the Rh(D)-positive RBCs to adhere, and a series of 500 μl washes were performed with ice-cold MPBS followed by a final wash with PBS. A total of 3 washes were performed for the first 2 rounds of panning and a total of 6 washes were performed for all subsequent pannings. For each panning, the first wash was carried out at a flow rate of 10 μl/minute during which time the bulk of Rh(D)-negative RBCs washed off the column. All subsequent washes were performed at 200 μl/minute. Following the last wash, the column was removed from the magnetic field and the bead-coated/phage-coated Rh(D)-positive RBCs were flushed off the column with 500 μl PBS using the plunger from a 5 cc syringe (Becton-Dickinson, Franklin Lakes, N.J.).
The RBCs were immediately centrifuged for 5 seconds at 13,000×g and were then resuspended in 200 μl of 76 mM citrate, pH 2.4, to denature the Rh(D) antigen and elute bound phage. Following a 10 minute incubation period at RT with intermittent vortexing, the phage eluate and cellular debris were neutralized with 18 μl 2 M Tris base and were added to 10 ml of O.D.=1.0 XL1-Blue strain of E. coli (Stratagene, La Jolla, Calif.) grown in super broth (SB) (Barbas et al., 1991, supra) supplemented with 10 μg/ml tetracycline. After incubation for 15 minutes at RT, during which time the phage library enriched for Rh(D) binders was allowed to infect the bacterial culture, 10 ml of pre-warmed, 37° C. SB containing 40 μg/ml carbenicillin/10 μg/ml tetracycline was added to give final antibiotic concentrations of 20 μg/ml and 10 μg/ml, respectively. A small aliquot of culture (˜100 μl) was immediately removed and titered on Luria broth/carbenicillin plates to determine the number of phage contained in the total eluate. The balance of the culture was shaken at 37° C. for 1 hour at 300 RPM. Additional antibiotics, additional SB, and VCSM13 helper phage were subsequently added and the culture was grown overnight at 30° C. as described (Siegel et al., 1994, supra).
Phagemid particles were purified from the culture supernatant by polyethylene glycol 8000 (PEG) precipitation (Barbas et al., 1991, supra), resuspended in 1% bovine serum albumin (BSA)/PBS, and dialyzed overnight to remove residual PEG that may lyse RBCs during subsequent rounds of panning. Thus, the resultant phage preparation serves as the input for the next round of panning. The γ1κ and γ1λ phage libraries were panned separately to prevent any bias in light chain isotype replication possibly introduced by bacterial amplification.
Screening Polyclonal Fab/phage Libraries and Individual Phage Colonies for Anti-Rh(D) Reactivity
The specificity of Fab/phage for the Rh(D) antigen was assessed using anti-M13 antibody as a bridging antibody to induce agglutination between RBCs that have bound anti-Rh(D) Fab/phage. One hundred μl aliquots of polyclonal Fab/phage from rounds of panning, or monoclonal Fab/phage derived from individual Fab/phage eluate clones, were incubated with 50 μl of a 3% suspension of RBCs of defined phenotype (i.e., Rh(D)-negative or -positive).
Following 1 hour incubation at 37° C., the RBCS were washed 3 times with 2 ml cold PBS to remove unbound Fab/phage. The resultant RBC pellets were resuspended in 100 μl of a 10 μg/ml solution of sheep anti-M13 antibody (5-Prime 3-Prime, Boulder, Colo.) and transferred to the round-bottomed wells of a 96-well microtiter plate. Plates were left undisturbed (˜2 hours) and were then read. Wells having a negative reaction exhibit sharp ˜2 millimeter diameter RBC spots whereas in wells having positive reactions, i.e., agglutination, the RBCs in agglutinated wells form a thin carpet coating the entire floor of the well.
For hemagglutination assays utilizing mini-column gel cards (ID-Micro-Typing System, Ortho Diagnostics, Raritan, N.J.) (Lapierre et al., 1990, Transfusion 30:109-113), 25 μl of Fab/phage clones were mixed with 50 μl aliquots of RBCs (0.8% suspensions in Micro Typing System buffer, Ortho Diagnostics). The mixtures were placed in the reservoirs above the mini-columns which contain dextran-acrylamide beads previously suspended in 100 μl/ml anti-M13 antibody. After incubation at 37° C., the gel cards were centrifuged at 70×g for 10 minutes and were read.
Miscellaneous Methods
Preparation of fluorescently-labeled RBCs for flow cytometry was performed as described herein and samples were analyzed using a FACScan microfluorimeter equipped with Lysis II (Ver 1.1) software (Becton-Dickinson, Mountain View, Calif.). Plasmid DNA was prepared from bacterial clones (Qiawell Plus, Qiagen, Chatsworth, Calif.). Double-stranded DNA was sequenced using light chain or heavy chain Ig constant region reverse primers or unique pComb3 vector primers that anneal 5-prime to the respective Ig chain (Barbas et al., 1991, supra; Roben et al., 1995, J. Immunol. 154:6437-6445) and automated fluorescence sequencing (Applied Biosystems, Foster City, Calif.). Sequences were analyzed using MacVector Version 5.0 sequencing software (Oxford Molecular Group, Oxford, UK) and the Tomlinson database of Ig germline genes (Tomlinson et al., 1996, V Base Sequence Directory. MRC Center for Protein Engineering, Cambridge, UK).
Experimental Design for Cell Incubation and Separation Protocols
The experimental conditions described above for panning Fab/phage libraries for anti-RBC-reactive phage were determined after performing a series of initial studies aimed at optimizing the cell separation process and ultimate yield of antigen-specific Fab/phage. The main parameters investigated included:
Biotinylation Conditions were sought that would biotinylate the RBC surface in a manner such that a sufficient number of streptavidin-coated magnetic beads would bind to the cells causing the RBCs to be retained by a magnetic column. In this case, over-biotinylation that might destroy the antigenicity of the Rh(D) antigen or might make the cells non-specifically absorb antibody is to be avoided. To address this issue, Rh(D)-positive/Kell-negative RBCs (Kell being a RBC antigen; (Walker, ed. 1993, In: Technical Manual, 11th Ed., Bethesda, Md., American Association of Blood Banks) were incubated with a range of sulfo-NHS-LC-biotin concentrations and the degree of biotinylation was assessed by flow cytometry utilizing fluorescein-conjugated streptavidin.
To assess the degree of cell-surface biotinylation, 5 μl aliquots of 3% suspensions of Rh(D)-positive/Kell-negative RBCs biotinylated at varying biotin reagent concentrations were incubated with 200 μl of a 1/100 dilution of FITC-streptavidin (Jackson ImmunoResearch, Bar Harbor, Me.) for 30 min at 4° C. (FIG. 2). The mixture was washed with phosphate buffered saline (PBS) and analyzed by flow microfluorimetry (—□—). Aliquots of cells were also analyzed for retention of Rh(D)-antigenicity (—Δ—) (i.e., specific staining) or for lack of non-specific staining (—◯—) by incubating the cells with 100 μl of either anti-Rh(D) or anti-Kell typing sera, respectively, washing the cells and then staining them with a 1/100 dilution of FITC-goat anti-human IgG (Jackson ImmunoResearch).
A linear, non-saturating response was observed (FIG. 2). Retention of Rh(D) antigenicity was assessed using anti-Rh(D) typing serum and was found to be unaffected by the derivatization of cell-surface proteins with biotin at all biotin concentrations tested (FIG. 2). Furthermore, the Kell-negative RBCs did not non-specifically adsorb anti-Kell antibodies.
Each biotinylated RBC sample was then incubated with an excess of streptavidin-coated magnetic microbeads and applied to a magnetic separation column. It was determined that as many as 108 RBCs could be retained by the column for RBC samples biotinylated with greater than or equal to 500 μg/ml biotin reagent. Since the actual RBC/phage panning experiments were designed to use only ˜107 Rh(D)-positive cells (see below), RBC biotinylation at 500 μg/ml was determined to be sufficient.
Concentration of Rh(D)-positive and Rh(D)-negative RBCs in Incubation Mixture
Prior to performing Fab/phage panning experiments, the ability of the magnetically-activated cell separation technique to separate Rh(D)-positive and Rh(D)-negative cells was assessed using anti-Rh(D) typing serum and flow cytometry (FIG. 3). Streptavidin-microbead coated, biotinylated Rh(D)-positive RBCs (8×106 cells) were mixed with a 10-fold excess of Rh(D)-negative non-coated RBCs (8×107 cells) in a 40 μl volume of PBS containing 2% non-fat dry milk (MPBS) and the mixture was applied to a MiniMACS column. The column was washed and the bound cells were eluted as described herein. Aliquots of RBCs contained in the original admixture (panel a), the column wash (panel b), and the column eluate (panel c) were stained with anti-Rh(D) typing serum and FITC-goat anti-human IgG as described in FIG. 2. The flow cytograms show that although ˜90% of the cells in the column load were Rh(D)-negative (panel a), nearly all of them washed off of the column (panel b), yielding a column eluate that was almost entirely Rh(D)-positive cells (panel c). Since only ˜6% of the final eluate comprise Rh(D)-negative cells (panel c), and Rh(D)-negative cells were initially present in a 10-fold excess to Rh(D)-positive cells, only ˜0.6% of the initial antigen-negative immunosorbent cells contaminated the final antigen-positive preparation. This efficiency of the cell separation was deemed adequate for subsequent panning experiments with Fab/phage.
In the above-described experiment, to avoid clogging the magnetic separation column, it was necessary to load the column in the absence of a magnetic field. This necessitated a reaction volume of less than or equal to 40 μl so that none of the material would run off the column. On theoretical grounds (Kretzschmar et al., 1995, Anal. Biochem. 224:413-419), one can calculate the appropriate concentration of cells required in a 40 μl volume to capture greater than 50% of Fab/phage specific for a given cell surface antigen. Such a calculation is a function of the number of antigen sites per cell and the dissociation constant (KD) of the bound Fab/phage. Using a value of ˜100,000 Rh(D) antigen sites per RBC (phenotype “-D-/-D-”) (Mollison et al., 1993, In: Blood Transfusion in Clinical Medicine, Oxford, Blackwell Scientific Publications) and the desired Fab/phage affinity in the KD=10−8 to 10−9 M range, then 8×106 Rh(D)-positive RBCs in a 40 μl reaction volume would be required. Given this number of Rh(D)-positive cells, a 10-fold excess of Rh(D)-negative RBCs was found to be the maximum amount of antigen-negative cells that could be effectively separated from antigen-positive RBCs by the magnetic column (FIG. 3).
Construction and Panning of Fab/phage Libraries
γ1κ and γ1λ phage libraries were prepared as described herein and were found to contain 7×107 and 3×108 independent transformants, respectively. Table 1 tabulates the panning results for the libraries.
An RBC agglutination assay utilizing anti-M13 secondary antibody as bridging antibody was used to detect anti-Rh(D) Fab/phage activity in the panned polyclonal libraries and the individual randomly-picked Fab/phage clones (FIG. 4). The results shown are a representative example of the assay depicting negative reactivity to Rh(D)-negative RBCs and strongly positive reactivity to Rh(D)-positive RBCs for the γ1κ library (panning #2) out to a dilution of 1/2048.
In the case of the γ1κ library, significant enrichment for binding phage appears to occur after only one round of panning, whereas significant enrichment for the γ1λ library occurs during the second round. This is reflected by both the sharp increase in the percent of phage bound during a given round of panning as well as the ability of the polyclonal γ1κ and γ1λ Fab/phage libraries to agglutinate Rh(D)-positive RBCs after 1 and 2 rounds of panning, respectively (Table 1, FIG. 4).
Monoclonal Fab/phage were prepared from randomly-picked individual bacterial colonies obtained during each round of panning. It was apparent that by the third round of panning, all clones have anti-Rh(D) specificity (Table 1). To confirm that these Fab/phage have anti-Rh(D) specificity and are not binding to other unrelated antigens that may coincidentally be present on the particular Rh(D)-positive RBC and absent on the particular Rh(D)-negative RBC used in the agglutination assays, clones were screened against a panel of 11 Rh(D)-negative and-positive RBCs of varying blood group specificities to verify their anti-Rh(D) specificity (Walker, 1993, supra).
Clonal Analysis at the Genetic Level
To investigate the genetic diversity among the randomly picked anti-Rh(D) clones, plasmid DNA was prepared from each of the clones and the corresponding heavy and light chain Ig nucleotide sequences were identified. In Table 2 there is listed a number of attributes for each clone including the name of the most closely-related germline heavy or light chain Ig gene. More detailed analysis at the nucleotide level revealed that among all of the anti-Rh(D) binding clones, there were a large number of unique heavy and light chain DNA sequences (Table 3). Because of the random shuffling of heavy and light chain gene segments which occurs during the creation of a Fab/phage display library (Barbas et al., 1991, supra), it is evident that these heavy chains and light chains combined to form nearly 50 different anti-Rh(D) antibodies.
A detailed multiple alignment analysis of the predicted amino acid sequences revealed a total of twenty-five unique heavy chain, eighteen unique kappa light chain and twenty-three unique lambda light chain proteins. Due to the combinatorial effect during library construction, these heavy and light chain gene segments paired to produce fifty unique Fab antibodies (20γ1κ and 30γ1λ). Of interest, all twenty five unique heavy chains and nearly all of the eighteen unique kappa light chains were derived from only 5 VHIII or four VκI germline genes, respectively, while the lambda light chains were derived from a more diverse set of germline genes. Analysis of heavy and light chain nucleotide sequences from over sixty negative clones from the non-panned libraries were performed to verify the heterogeneity in variable region family representation before selection. Clones representing VH families I (13%), III (36%), IV (31%), V (15%) and VI (5%); Vκ families I (43%), II (14%), III (29%) and IV (14%); and Vγ families I (48%), II (4%), III (9%), IV (4%), V (9%), VI (17%) and VII (9%) were present.
Clonal Analysis at the Protein Level
To investigate the diversity in fine specificity (Rh(D) antigen epitope specificity) among the anti-Rh(D) clones, agglutination experiments were performed with selected clones and with sets of rare Rh(D)-positive RBCs which were obtained from individuals whose RBCs produce Rh(D) antigen lacking certain epitopes. Examining the pattern of agglutination of a particular anti-Rh(D) antibody with such sets of mutant RBCs enables the identification of the specific epitope on Rh(D) to which the antibody is directed (Mollison et al., 1993, supra). A representative example of such an experiment is shown in FIG. 5 and the Rh(D) epitopes for selected anti-Rh(D) Fab/phage clones are tabulated in Table 2.
Agglutination experiments were performed with anti-Rh(D)-negative RBCs (rr), Rh(D)-positive RBCs (R2R2), and “partial” Rh(D)-positive RBCs (mosaics IIIa, IVa, Va, VI, VII). The results shown are a representative example of the assay for 5 randomly-picked anti-Rh(D) Fab/phage clones (FIG. 5).
γ1κFAB/PHAGE LIBRARY PANNING RESULTS
γ1λFAB/PHAGE LIBRARY PANNING RESULTS
1panning round, where “0” represents the initial, non-panned Fab/phage library
2number of colony-forming units (CFUs) of phage (φ) incubated with Rh(D)-positive/-negative RBC admixture
3total number of CFUs of φ contained in eluate
4(φ output/φinput) × 100
5fold increase in % bound from compared to previous round of panning
6agglutination titer; see text and
7number of Rh(D)-binding Fab/phage clones per total number of clones screened from panning round; see Table 2 for details
1nomenclature: prefix “KPO” denotes “γ1κFab/phage library, panning 0”, “KP1” denotes “γ1κFab/phage library, panning 1”, etc.
2agglutination negative or positive against Rh(D)-positive RBC
3Ig heavy chain variable region gene family per Tomlinson et al., supra
4closest related Ig heavy chain variable region gene per Tomlinson et al. supra
5Ig light chain variable region gene family per Tomlinson et al., supra
6closest related Ig light chain variable region gene per Tomlinson et al., supra
7Rh(D) epitope as defined by rare RBC agglutination pattern (see FIG. 5 and text)
1nomenclature: prefix “LPO” denotes “γ1λFab/phage library, panning 0”, “LP1” denotes “γ1λFab/phage library, panning 1”, etc.
2agglutination negative or positive against Rh(D)-positive RBC
3Ig heavy chain variable region gene family per Tomlinson et al., supra
4closest related Ig heavy chain variable region gene per Tomlinson et al., supra
5Ig light chain variable region gene family per Tomlinson et al., supra
6closest related Ig light chain variable region gene per Tomlinson et al., supra
7Rh(D) epitope as defined by rare RBC agglutination pattern (see FIG. 5 and text)
Use of Fab/Phage Antibodies as Blood Bank Typing Reagents
The ability of the anti-Rh(D) Fab/phage preparations to accurately distinguish Rh(D)-negative from Rh(D)-positive RBCs in microplate hemagglutination assays (
The gel test comprises a plastic card of approximately 5×7 cm, containing 6 mini-columns each filed with about 20 μl of dextran-acrylamide beads suspended in anti-human globulin (Coombs reagent). Red cells to be typed are incubated with the desired human anti-sera and are centrifuged through the gel. RBCs which are positive for antigens to which the antisera is directed agglutinate as they encounter the anti-human globulin and become trapped in or above the gel matrix. Unreactive RBCs sediment through the gel particles and form a pellet at the bottom of the microtube. Because the gel test offers a number of advantages over traditional blood banking methods for RBC phenotyping including decreased reagent volumes, the elimination of a cell washing step and a more objective interpretation of results, many blood bank facilities have adapted this new technology. As shown in
To perform the assay, Rh(D)-negative or -positive red blood cells were incubated with dilutions of anti-Rh(D) Fab/phage (γ1κ library, panning #2) and were centrifuged into micro-columns containing beads suspended in anti-M13 antibody. Undiluted Fab/phage stock had a titer of 5×1012 cfu/ml similar to that in the microplate settling assay (FIG. 4). Because the volume of Fab/phage used in this assay is one-fourth of that in the microplate assay, the amount of Fab/phage present in the 1/625 dilution is approximately equal to that present in the 1/2048 dilution in FIG. 4. Therefore, the number of Fab/phage required to yield a positive result is essentially equivalent in both assays.
In other assays which were performed as just described, when anti-M13 antibody was eliminated from the assay, no agglutination of red blood cells was observed. In addition, anti-IgG antibody does not react with recombinant Fabs expressed on the surface of the bacteriophage. Only Rh-positive cells which were reacted with anti-Rh phage were agglutinated when anti-M13 antibody was present in the assay. It should be noted that when high concentrations of anti-M13 antibody were used, even Rh-negative cells appeared to be agglutinated. This is an artifact resulting from the cross-linking of unbound (i.e., non-reacted) phage which becomes crosslinked in the presence of high amounts of anti-M13 antibody and forms a semi-impenetrable mat through which not all the Rh-negative cells can traverse. In the experiments described herein, an anti-M13 concentration of about 100 μg/ml was considered to be optimal for agglutination and for the prevention of false positive results. Depending on the precise concentrations of reagents and cells used in the assay, the concentration of anti-M13 may deviate from this number.
To assess the relative sensitivity of an anti-M13 modified Micro Typing System, the columns of the Micro Typing System cards had added to them 100 μg/ml of anti-M13 antibody. Rh-negative or Rh-positive red blood cells were incubated with undiluted or with five-fold serial dilutions (1/5, 1/25, 1/125, 1/625 and 1/3125) of anti-Rh phage antibodies. The cards were centrifuged and samples were assessed for agglutination. The modified Micro Typing System card assay was capable of detecting anti-Rh agglutination at a dilution of between 1/625 and 1/3125.
Procedures for isolation of tumor-specific antibodies
Fab/phage specific for tumor cells are useful for in vitro diagnosis (lab assays of biopsy, fluid, or blood samples), in vivo labeling of tumor/metastasis (coupling of antibody to imaging probe), or for treatment of malignancy (coupling of antibodies to chemical or radioactive toxins). Tumor-specific antibodies are also useful for the identification of novel antigens or markers on tumor cells which may form the basis for anti-tumor vaccines. Further, tumor-specific antibodies useful for the generation of anti-idiotypic antibodies may also form the basis for anti-tumor vaccines.
Anti-tumor antibodies are generated essentially as described herein for the generation of anti-Rh antibodies. Tumor cells, for example, but not limited to, malignant melanoma cells, are cell-surface biotinylated, labeled with streptavidin-magnetic microbeads, and are then mixed with excess normal melanocytes. Fab/phage libraries are generated from peripheral blood lymphocytes of melanoma patients who possess therapeutically useful anti-tumor antibodies. A number of melanoma patients who have “cured” themselves apparently have done so by mounting a humoral (i.e., antibody) immune response. These Fab/phage libraries are incubated with the admixture of cells. Fab/phage which are directed against epitopes specific for malignant cells will bind to the malignant cells and may then be isolated utilizing the magnetic column panning approach.
Isolation of Fab/phage that identify bacterial virulence factors
The approach described herein may be used to isolate Fab/phage capable of detecting differences between the virulent bacteria and their nonpathogenic counterparts. In this case, the virulent strain of bacteria is magnetically labeled, diluted with the non-pathogenic counterpart, and an Fab/phage library which is generated from lymphocytes obtained from individuals infected with the virulent strain is added. Fab/phage which are isolated in this manner may be useful for the identification of novel bacterial antigens against which antibacterial compounds and/or vaccines may be developed.
Clinically, the human Rh(D) antigen is the most important red blood cell (RBC) membrane protein in transfusion medicine. The alloimmune response against Rh(D) produces high affinity IgG antibodies which cause hemolytic transfusion reactions and hemolytic disease of the newborn (HDN). The prophylactic use of Rh(D)-immune globulin in pregnant Rh(D)-negative women has been a major advance in the prevention of HDN, yet the mechanism by which the drug exerts its immune modulatory effect is not well understood.
Monoclonal antibodies derived from the B cells of Rh(D)-immune globulin donors have defined several dozen Rh(D) epitopes (Scott, 1996, Transfus. Clin. Biol. 3:333). Paradoxically, the Rh(D) antigen, a circa 30 kD transmembrane protein, has minimal extracellular mass and presents a very limited surface area for epitope expression. Because molecular cloning of a large repertoire of anti-Rh(D) antibodies has not previously been performed, these observations remain non-reconciled.
Rational development of recombinant formulations of Rh(D)-immune globulin would be facilitated by molecular cloning of a large number of anti-Rh(D) antibodies. Such cloning would also aid in the design of therapeutic agents that block antibody binding. Furthermore, comprehensive genetic analysis of anti-Rh(D) antibodies within a given alloimmunized individual would serve as a paradigm for human immune repertoire development, an area of which limited information is currently available. Previously, no more than 8 IgG anti-Rh(D) human monoclonal antibodies have been derived from a single individual (Boucher et al., 1997, Blood 89:3277).
In Example 1, a technique useful for isolating Fab/phage antibodies directed against antigens expressed on cell surfaces was described. Using this technique and intact human red blood cells (RBCs), highly diverse γ1κ and γ1λ. Fab/phage libraries against the Rh(D) antigen from the B cells of a single Rh(D)-immune globulin donor were generated.
In this Example, a detailed genetic and serological analysis of 53 unique anti-Rh(D) antibodies derived from 83 randomly chosen clones is presented. These data demonstrate extensive genetic homology between antibodies directed against different Rh(D) epitopes. Evidence is provided herein that antibodies directed against different epitopes can be clonally related. Finally, a model is described which reconciles the serological diversity of anti-Rh(D) antibodies with the topological constraints imposed by the Rh(D) antigen.
The materials and methods used in the experiments presented in this Example are now described.
Production of Monoclonal Anti-Rh(D) Phage-displayed and Soluble Fab Molecules
Methods for the isolation of human anti-Rh(D)-specific antibodies from γ1κ and γ1λ Fab/phage display libraries using the pComb3H phagemid vector and a cell-surface panning protocol have been described (Siegel et al., 1997, J. Immunol. Meth. 206:73). Soluble anti-Rh(D) Fab preparations for inhibition studies were produced from bacterial cultures transfected with plasmid DNA from which the M13 gene III coat protein sequence had been excised as described (Siegel et al., 1994, Blood 83:2334; Barbas et al., 1991, Methods: A Companion to Meth. Enzymol. 2:119). Cultures were grown by shaking at 300 RPM at 37° C. in superbroth (30 g/L tryptone, 20 g/L yeast, 10 g/L MOPS, pH 7.00) containing 20 mM MgCl2 and 50 mg/ml carbenicillin to an OD600 of 0.5. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to 1 mM and cultures were shaken overnight at 30° C. Bacterial pellets were harvested and resuspended in {fraction (1/50)}th of the initial culture volume with osmotic shock buffer (500 mM sucrose, 1 mM EDTA, 100 mM Tris, pH 8.00), incubated for 30′ at 4° C., and centrifuged at 16,000×g for 15′ at 4° C. Fab-containing supernatants were dialyzed against PBS and used in agglutination experiments without further purification.
Anti-Rh(D) Antibody Binding Assays
The binding of anti-Rh(D) Fab/phage or soluble Fab molecules to normal or partial Rh(D) antigens was assessed by indirect agglutination assays as described (Siegel et al., 1994, Blood 83:2334; Siegel et al., 1997, J. Immunol. Meth. 206:73). Briefly, 100-μl aliquots of phage-displayed Fabs or soluble Fabs were incubated with 50 μl of a 3% suspension of RBCs. Following a one-hour incubation at 37° C., the RBCs were washed 3 times with 2 ml of cold PBS to remove unbound antibody. The resulting RBC pellets were resuspended in 100 μl of a 10 μg/ml solution of sheep anti-M13 antibody (5 Prime-3 Prime, Boulder, Colo.) for Fab/phage experiments or goat anti-human κ or λ light chain antibody (Tago, Burlingame, Calif.) for γ1κ or γ1λ soluble Fab experiments, respectively. The RBC suspensions were transferred to the round-bottomed wells of a 96-well microplate and left undisturbed for 2 hours. Negative reactions show sharp ˜2 millimeter diameter RBC spots whereas the RBCs in agglutinated wells form a thin carpet coating the entire floor of the well (Siegel et al., 1997, J. Immunol. Meth. 206:73). Agglutination titers for recombinant antibodies were determined by performing serial 2-fold dilutions in 1% BSA/PBS. Typically, Fab/phage had agglutination titers of 1/1024 to 1/2048 (where “neat” is defined as 5×1012 cfu/ml; Siegel et al., 1997, J. Immunol. Meth. 206:73) and soluble Fabs had agglutination titers of 1/64 to 1/128 when prepared as described above.
For determining Rh(D) epitope specificity for anti-Rh(D) Fab/phage antibodies, the following reference Rh(D) variant cells were used: O/DIIIaCce, G positive; B/DIIIcCce; A/DIVace; A/DIVace; O/DIVace; O/DIVbCce; B/DIVbCce, Goa negative, Rh32 negative; O/DVaCce; O/DVacEe, Dw positive; O/DVICce; B/DVICce; AB/DVICce; A/DVIcEe; O/DVIICce; and O/DVIICce. Each Fab/phage antibody was tested on at least 3 separate occasions against at least 2 different examples of each variant cell type and identical epitope assignments were obtained each time. For antibodies that demonstrated not-previously-described patterns of reactivity or repeatedly weak reactivity against one type of cell, monoclonal Fab/phage were prepared on a least 4 separate occasions to verify the patterns of reactivity.
For inhibition studies, the ability of antibodies with different Rh(D) epitope specificities to compete with each other for binding was assessed by preparing stocks of each clone in both a soluble Fab form and a phage-displayed form. Pair-wise combinations of soluble Fabs and Fab/phage were prepared and added to Rh(D)-positive RBCs. The resulting incubation mixes comprised 50 μl of a 3% suspension of RBCs, 100 μl of undiluted soluble Fab, and 100 μl of Fab/phage diluted to its highest agglutinating titer. Following a 1-hour incubation at 37° C., RBCs were washed, resuspended in anti-M13 antibody, and placed in microplate wells as described above. That the amount of soluble Fab present in an incubation mixture was sufficient to compete away a Fab/phage that shared the same binding site was determined by verifying that each soluble Fab preparation could block its own Fab/phage.
Inhibition experiments were also performed using pair-wise combinations of soluble Fabs instead of soluble Fab and Fab/phage combinations. In this type of experiment, pairs of soluble Fabs specific for different epitopes were chosen such that one Fab contained a λ light chain and the other a κ light chain. Incubations with RBCs were performed with one Fab in excess and the other in limiting amounts. Blocking of the latter antibody was assessed using a secondary antibody (anti-λ or anti-κ) specific for its light chain isotype.
Nucleotide Sequencing and Analysis
Plasmid DNA for sequencing was prepared using the Qiawell™ system (Qiagen, Chatsworth Calif.). Double-stranded DNA was sequenced using light chain or heavy chain imnunoglobulin constant region reverse primers or a set of unique pComb3H vector primers that anneal 5′ to the respective immunoglobulin chain (Barbas et al., 1991, Methods: A Companion to Meth. Enzymol. 2:119; Roben et al., 1995, J. Immunol. 154:6437) and automated fluorescence sequencing (Applied Biosystems, Foster City, Calif.). Sequence analysis and variable region germline assignments were performed using DNAplot (Althaus et al., 1996, DNAPLOT, http://www.mrc_cpe.cam.ac.uk/imt_doc/DNAsearch.html) and the V Base Directory of Human V Gene Sequences (March 97 update; Tomlinson et al., 1996, V Base Directory of Human V Gene Sequences, http://www.mrc_cpe.cam.ac.uk/imt_doc/vbase_home_page.html). Germline assignments were corroborated with the MacVector (v. 6.0) software package (Oxford Molecular Group, Oxford, UK) against the same database. Multiple sequence alignments and predictions of isoelectric point were calculated using the Pileup and Isoelectric programs of the GCG software package (v. 8.0.1; GCG, Madison, Wis.). Statistical analysis was performed with Statview (Abacus Concepts, Berkeley Calif.).
The results of the experiments presented in this Example are now described.
Sequence Analysis of Anti-Rh(D) Heavy and Light Chains
Example 1 describes the use of Fab/phage display and cell-surface panning to isolate a large array of anti-Rh(D) antibodies from the peripheral blood lymphocytes of a single hyperimmunized donor. Separate γ1κ and γ1λ Fab/phage display libraries were constructed and contained 7×107 and 3×108 independent transformants, respectively, based on electroporation efficiency. Each library was panned independently using a simultaneous positive/negative selection strategy with magnetically-labeled Rh(D)-positive RBCs and unmodified Rh(D)-negative RBCs as described. Following two rounds of panning, 32 of 36 γ1λ and 15 of 15 γ1κ clones were positive for anti-Rh(D) activity. After the third round of panning, 24 out of 24 γ1λ and 12 out of 12 γ1κ clones were positive. Nucleotide sequencing of the 83 positive clones revealed a total of 28 unique heavy and 41 unique light chains. Due to combinatorial effects during phage display library construction, heavy and light chain gene segments paired to produce 53 unique Fab antibodies.
Anti-Rh(D) Heavy Chains
All of the heavy chain sequences used VHIII family-encoded gene products, as indicated in
Neither JH nor D segments showed restriction. At least 9 different D segments were used and JH gene utilization comprised JH6 (5 VDJs and 9 clones), JH4 (4 VDJs and 10 clones), JH3 (2 VDJs and 8 clones) and JH5 (1 VDJ and 1 clone). All four VH genes were Chothia class 1-3 (Chothia et al., 1992, J. Mol. Biol. 227:799), and the CDR3s showed a narrow range of length from 15 to 19 residues.
Because rearranged heavy chain genes demonstrate extensive diversity, clones sharing identical VDJ rearrangements are generally considered to have arisen from the same clone. Based upon nucleotide alignment with the germline genes, the ontogeny tree in
Anti-Rh(D) Light Chains
Seventeen of the 18 κ light chains were from the VκI family and the remaining light chain originated from a VκII family member germline gene (FIG. 10). Only four Vκ germline genes were used (15 clones were derived from DPK9 alone), and the κ light chain clones had between 1 and 49 mutations from their corresponding Vκ germline genes. All five of the known Jκ genes were used and were each joined to the DPK9 gene in one or more clones. Because the light chains showed considerably less diversity in their joining regions than the heavy chains, it was difficult to assign common clonal origins. However, an ontogeny tree was constructed by grouping common V and J gene segments along with common mutations. Based upon this analysis, the 18 κ chains comprised at least 10 different recombination events.
λ light chains were restricted by their Jλ gene usage but showed no restriction in their use of Vλ genes (FIG. 11). The 23 λ light chains all used the Jλ2Vasicek gene but were derived from VλI (12 clones), VλIII (5), VλVII (3), VλII (2) and VλIV (1) family genes. The number of mutations ranged from 2 to 41 from the nearest germline Vλ gene. Based upon common joining regions and mutations, these 23 1 light chains were derived from at least 13 different B cells.
Assessment of the Diversity of the Non-panned Libraries
In order to determine whether the apparent restriction in gene usage of the anti-Rh(D) antibodies could have been due to pre-selection factors (i.e. cloning artifacts), the diversity of the non-panned γ1κ and γ1λ Fab/phage libraries was assessed. By sequencing 39 randomly-picked clones, we determined that there were no duplicate heavy or light chain sequences, and that there was significant heterogeneity in V gene family representation before selection (FIG. 12). In fact, the variable region gene family distribution was not unlike that found by other investigators for IgG-secreting lymphocytes in adult peripheral blood (Stollar, 1995, Ann. NY Acad. Sci. 764:547). Furthermore, of the 14 VHIII-encoded negative clones, only one used a VH3-33 superspecies germline gene (VH3-30.3); the other 13 were encoded by VH3-07 (3), 3-09 (2), 3-15 (2), 3-48 (2), 3-72 (2), 3-23 (1), and DP-58 (1). Therefore, the restriction of the 83 anti-Rh(D) clones to the VH3-33, 3-30, 3-30.3 and 3-21 genes is significant and not a result of skewed representation of certain germline genes within the originally constructed γ1κ and γ1λ Fab/phage libraries.
Heavy and Light Chain Contribution to Rh(D) Epitope Specificity
Because of the conformational dependency of Rh(D) antigenicity, Rh(D) “epitopes” have been classically defined through the use of RBCs obtained from rare individuals whose cells appear to produce Rh(D) antigens “lacking” certain epitopes. Examining the pattern of agglutination of a particular anti-Rh(D) monoclonal antibody with such sets of partial Rh(D) RBCs enables one to categorize that antibody's fine specificity.
Monoclonal Fab/phage preparations were prepared in triplicate for each of the 53 anti-Rh(D) clones and tested against a panel of Rh(D) category cells IIIa/c, IVa, IVb, Va, VI, and VII. This panel of cells can differentiate between the Rh(D) epitope specificities as described by Lomas et al. (1989, Vox Sang 57:261; designated epitopes epD1, epD2, epD3, epD4, epD5, and epD6/7). Agglutination experiments using the Fab/phage clones demonstrated five different patterns of reactivity, including a new pattern which had not been described in the original study by Lomas et al. or in the more recently-described (Scott, 1996, Transfus. Clin. Biol. 3:333; Stollar, 1995, Ann. NY Acad. Sci. 764:547) 9-, 30-, or 37-epitope systems (as indicated by the data depicted in FIGS. 13 and 14). Although nearly all Fab/phage gave unequivocal agglutination reactions, a few antibodies gave repeatedly weak patterns of reactivity against one of the panel cells. For these reactions, monoclonal Fab/phage were prepared on at least 4 separate occasions to verify the patterns of reactivity.
The most commonly-recognized epitope was epD6/7, against which 13 of the clones described herein were directed. Interestingly, monoclonal anti-Rh(D) clones isolated using conventional tissue culture methods are most often specific for epD6/7 (Mollison et al., 1993, In: Blood Transfusions in Clinical Medicine, 9th ed., Blackwell Scientific, Oxford, U.K.). EpD2, epD1, and epD3 were recognized by 10, 7, and 2 clones, respectively. Six clones agglutinated cells of categories IIIa/c, IVa, and VII, but not of categories IVb, Va, and VI, and were designated anti-“epDX”. This pattern is identical to epD1, except that the IVa cell is agglutinated. Three clones gave intermediate reactions with cell IVa, but otherwise showed patterns consistent with epDX or epD1. These clones were designated epDX1 or epD1X depending on whether this reactivity against cell IVa was stronger or weaker, respectively (see FIG. 14). Similarly, reaction patterns for epD1 and epD2 differ by a positive reaction with the category Va cell; therefore, one clone was given epD21 specificity because it gave only moderate reactivity against that cell. Such variable reactions against one or more partial Rh(D) cells have been observed for anti-Rh(D) monoclonal antibodies produced through conventional tissue culture methods (Tippett et al., 1996, Vox Sang. 70:123).
Because of the reassortment of heavy and light chain gene segments that occurs during the construction of a phage display library, a number of clones were isolated that shared either a heavy (e.g. E1) or light (e.g. M3) chain sequence (FIG. 14). Some heavy chains were found to have paired with both κ and λ light chains (e.g. C1, D20) and each demonstrated anti-Rh(D) specificity. Interestingly, some heavy chains (e.g. E1, D12) mapped to different epitopes depending upon the light chains with which they were paired. In particular, the light chains of two such clones, E1/M2 and E1/M3, differed by only three amino acid residues (
Inhibition Studies
To investigate the topological relationships among the Rh(D) epitopes, inhibition studies were performed. Gorick et al. (1988, Vox Sang. 55:165) used pairs of non-labeled and 125I-labeled anti-Rh(D) monoclonal antibodies to demonstrate that antibodies to at least three different Rh(D) epitopes (subsequently identified as epD 1, D6 and D7; Lomas et al., 1989, Vox Sang. 57:261) could inhibit one another. Recombinant antibodies to five Rh(D) epitopes were used to confirm and extend those findings (FIG. 15). In one series of experiments, the ability to express each antibody in both a soluble Fab as well as phage-displayed form was exploited to determine whether a soluble Fab directed against one epitope would inhibit the agglutination induced by an Fab/phage directed against a different epitope. Reciprocal pairs of soluble Fab and Fab/phage specific for epD1, epD2, epD3, epD6/7, and epDX were tested. All ten combinations showed mutual inhibition patterns (illustrated in
Isoelectric Point Analysis of Anti-Rh(D) Antibodies
The restriction in VH germline gene usage to only four VHIII family members was intriguing in light of their ability to confer specificity to a number of Rh(D) epitopes. VH germline gene segments used to encode anti-Rh(D) antibodies are among the most cationic segments available in the human VH repertoire which may be used to account for the relatively high pI of polyclonal anti-Rh(D)-containing antisera (Boucher et al., 1997, Blood 89:3277; Abelson et al., 1959, J. Immunol. 83:49; Frame et al., 1969, Immunology 16:277). Although the cationic nature of the antibodies may be important for binding to Rh(D), a constitutive net positive charge may be necessary to permeate the highly negative RBC ζ potential, thus permitting antibody to contact antigen (Mollison et al., 1993, In: Blood Transfusion in Clinical Medicine, 9th ed., Blackwell Scientific, Oxford, U.K.). In either case, analysis of the predicted pI for the 28 heavy chains and 41 light chains isolated here showed an interesting phenomenon for the heavy chains, as compared with the light chains. Using the pI interval scale of Boucher et al. (1997, Blood 89:3277), the average pI of the four germline VH segments used to encode the 28 heavy chains is high (9.87±0.15), significantly higher than that of 39 randomly-picked, non-Rh(D) binding clones from the original non-panned libraries (9.24±0.80, P<10−5). Similar to the results of Boucher et al., the addition of D and JH segments and the introduction of somatic mutation did not significantly change the pI of the average anti-Rh(D) heavy chain (9.81±0.33, P<0.37). However, for the light chains, the average pI of their germline counterparts was not cationic, but the light chains became so through the addition of JL segments and somatic mutation. Overall, for all 18 κ and 23 λ light chains, paired t-test analyses before and after somatic mutation showed a significant increase in net positive charge when comparing germline VL (6.63±1.47) with expressed VL (7.28±1.51, P<10−3) or germline VLJL (7.43±1.47) with expressed VLJL (8.55±1.35, P<10−7). There was no significant increase in a similar analysis of 16 non-Rh(D) binding clones (P<0.59 and P<0.19, respectively). Examination of the light chain sequences listed in
Conventional and Phage-displayed Anti-Rh(D) Monoclonal Antibodies
The phage-display derived anti-Rh(D) clones were compared with those produced by conventional tissue culture techniques (EBV-transformation and cell fusion). Despite the relatively small number of previously-published sequences for IgG anti-Rh(D) antibodies (N=21) and the fact that they were derived from over 10 different donors, there was surprisingly good correlation between the two groups, as indicated in Table 3. Both cohorts demonstrated a predominance of VHIII-family encoded germline genes, particularly those of the VH3-33 superspecies. CDR3 regions had similar lengths ranging from 15-19 residues for Fab/phage antibodies and 16-20 for conventional monoclonal antibodies, although one heterohybridoma was an outlier, having a CDR3 length of 28 residues. κ light chains were biased towards Vκ1 family members and λ light chains demonstrated the preferential use of the Jλ2Vasicek gene. The only qualitative discrepancy was in Vλ family usage where Fab/phage clones demonstrated a slight preference for VλI vs. VλIII family members for conventional monoclonal antibodies. However, in both cohorts, DPL16 was used more often than any other λ light chain gene.
It has been suggested in the literature that the VH4-34 (VH4.21) germline gene, a gene used by many autoantibodies and cold agglutinins, may play an important role in the immune response to Rh(D) (Silberstein et al., 1991, Blood 78:2377; Pascuel et al., 1991, J. Immunol. 146:4385; Silverman et al., 1988, J. Exp. Med. 168:2361; Thompson et al., 1991, Scand. J. Immunol. 34:509). However, these conclusions arose from the analysis of IgM monoclonal antibodies and only 2 of the 21 published anti-Rh(D) IgG sequences used VH4-34 (Bye et al., 1992, J. Clin. Invest. 90:2481). In a related series of experiments, aliquots of the γ1κ and γ1λ libraries obtained after the second and third rounds of selection were pooled and then panned against the VH4-34 specific rat anti-idiotypic monoclonal antibody (9G4; Stevenson et al., 1989, Br. J. Haematol. 72:9). Although VH4-34 encoded antibodies were successfully enriched, the Fab/phage were not specific for Rh(D) and displayed serological characteristics similar to those of cold agglutinins.
Rh(D) Epitopes and Significance of Antibody Sequences
Since the initial report by Argall et al. in 1953 (J. Lab. Clin. Med. 41:895), it has been recognized that rare individuals who type as Rh(D)-positive can produce allo-anti-Rh(D) antibodies in response to Rh(D) immunization by transfusion or pregnancy. This phenomenon was explained by hypothesizing that the Rh(D) antigen is a “mosaic structure” and that these individuals were producing alloantibodies to parts of the mosaic they lack. By systematically examining patterns of reactivity between their cells and sera, RBCs expressing partial Rh(D) antigens were divided into categories, each presumed to have a different abnormality in their Rh(D) antigen. Through the subsequent use of index panels of monoclonal anti-Rh(D) antibodies, a series of epitopes were defined of which the number and combination varied from one Rh(D) category to another. As new monoclonal antibodies were produced, their reactivity profiles against these partial Rh(D) RBCs became the standard method for determining Rh(D) antibody epitope specificity. Molecular analyses of partial Rh(D) phenotypes have shown that the Rh(D) genes in these individuals have either undergone intergenic recombination with the highly homologous Rh(CE) gene, or, less commonly, have sustained point mutation(s) (Cartron et al., 1996, Transfus. Clin. Biol. 3:497).
As noted earlier, to investigate the topological relationships among Rh(D) epitopes, Gorick et al. performed competition experiments with Rh(D) monoclonal antibodies and observed varying degrees of inhibition (Gorick et al., 1988, Vox Sang. 55:165). These results, when combined with those of Lomas et al. (1989, Vox Sang. 57:261), suggested a model for Rh(D) in which epitopes are spatially distinct yet demonstrate a certain degree of overlap as illustrated in FIG. 16A. This model explained how antibodies to two different Rh(D) epitopes (in this case epD2 and epD3) could inhibit each other's binding to wild type Rh(D), and how a change in the structure of Rh(D) in category VI RBCs (asterisk in
Several hypotheses could account for these findings. The most simplistic interpretation is that the heavy chain does not directly interact with the antigen, but rather is responsible for bringing the antibody in close proximity with the antigen. The specific interactions between the light chain and the antigen would then determine the epitope specificity for that antibody. In this regard, the data presented herein are consistent with the observations of Boucher et al. (1997, Blood 89:3277) on the relative cationic nature of anti-Rh(D) heavy chains. However, because it was determined during the studies described herein that light chains become cationic during somatic mutation, the charge of the entire antibody may play a role in its ability to bind, resulting in the selection and expansion of particular B-cell clones.
A more compelling hypothesis is that Rh(D) epitopes do not differ spatially but differ only in the number and arrangement of contact residues presented, as illustrated in FIG. 16B. In other words, the “footprints” of most, if not all, anti-Rh(D) antibodies are essentially identical to one another. The genetic events which produce partial Rh(D) molecules result in the loss of certain critical key points of contact necessary for some antibodies to bind; alternatively, they result in the formation of new structures that interfere with the binding of other anti-Rh(D) immunoglobulins. For example, the introduction of a “ledge” in Rh(D) category VI cells (asterisk in
This model is consistent with the inhibition experiments described herein (e.g.
This concept of “coincident” epitopes is best exemplified by comparing the E1/M2 and E1/M3 clones described herein. The only difference between the reactivity of E1/M2 and E1/M3 is the ability of the latter antibody to agglutinate Rh(D) category VI cells, as depicted in FIG. 13. Hence, E1/M2 is classified as an anti-epD2 and E1/M3 as an anti-epD3 antibody. Light chains M2 and M3 differ by only 3 residues: D82A, G95aA, and W96V, as indicated in FIG. 11. Therefore, some combination of these three residues confers reactivity against category VI cells. In other words, epD2 and epD3, as seen by the E1/M2 and E1/M3 antibodies, differ by the binding constraints imposed by at most three mutations. If the model depicted in
Immunologic and Clinical Implications of Proposed Model
The model depicted in
It is herein postulated that somatic mutation of an anti-epD3 antibody can change its fine specificity to that of epD2 (or vice-versa, see FIG. 16C). Suppose that the preferred way of making an anti-epD2 antibody is through an anti-epD3 intermediate. To an Rh(D)-negative individual, this process can take place unimpeded. However, in a category VI individual, this route would be unfavorable because an anti-epD3 antibody would be self-reactive. As a result, such an individual would have to make anti-epD2 antibodies by alternative routes or by tolerating some degree of auto-reactivity in the process. With respect to the latter point, it is of interest to note that a transient production of auto-anti-Rh(D) frequently precedes or accompanies the early production of allo-anti-Rh(D) in individuals who express partial Rh(D) antigens (Chown et al., 1963, Vox Sang. 8:420; Macpherson et al., 1966, J. Clin. Pathol. 45:748; Beard et al., 1971, Med. Genet. 8:317; Cook 1971, Br. J. Haematol. 20:369; Holland et al., Transfusion 13:363 (Abstract); Issit, 1985, In: Applied Blood Group Serology, 3rd ed., Montgomery Scientific, Miami Fla.). It is predicted, therefore, that the anti-epD2 antibodies from a category VI individual would be different in composition (i.e. gene usage) and quite possibly quantitatively depressed as compared to an Rh(D)-negative individual. This may be analogous to the antibodies of the ABO blood group system in which it has been observed that anti-A and anti-B titers in blood group O individuals are significantly higher than in blood group B or A individuals, respectively (Ichikawa, 1959, Jap. J. Med. Sci. Biol. 12:1). Blood group O individuals are unconstrained in creating their anti-A and anti-B immune repertoires while individuals who produce A or B antigens (2 nearly identical structures) must do so in a manner that avoids self-reactivity.
In the case of antibodies E1/M2 and E1/M3, they appear to have arisen from a common precursor B cell rather than directly from each other (FIG. 1). To test the framework of the hypothesis presented herein, i.e. somatic mutation resulting in “epitope migration” of an antibody, one may construct the precursors and potential intermediates between the M2 and M3 light chains and then determine what Rh(D) epitope specificities (if any) they express. This concept of epitope migration has been previously reported for murine anti-cryptococcal and anti-type II collagen antibodies (Mukherjee et al., 1995, J. Exp. Med. 181:405; Mo et al., 1996, J. Immunol. 157:2440).
If the model proposed herein for Rh(D) epitopes is correct, then the question of the number of epitopes may be obsolete. There may be as many epitopes as can be differentiated by the number of cell categories, i.e. 2n epitopes where n is the number of distinct partial Rh(D) RBCs.
A more important question is the interrelationships between the various epitopes. For example, are some epitopes “further away” than others—not in the topological sense, but in terms of the number of mutational hits an antibody needs to receive in order to change its serologic reactivity. Furthermore, does the humoral immune response in a partial Rh(D) individual differ from that in an Rh(D)-negative individual in the manner predicted by this model? One may find that allo-anti-Rh(D) antibodies made by partial Rh(D) individuals are not as clinically significant, i.e. capable of inducing hemolysis. This may explain why hemolytic disease of the newborn due to anti-Rh(D) produced by pregnant individuals with partial Rh(D) phenotypes is so rare even when taking into account the low prevalence of the partial Rh(D) phenotypes (Mollison et al., 1993, In: Blood Transfusion in Clinical Medicine, 9th ed. Blackwell Scientific, Oxford, U.K.). A better understanding of the immune response to Rh(D) in these patients may alleviate concerns regarding the need to identify such individuals to ensure that they only receive Rh(D)-negative blood products for transfusion and Rh(D)-immune globulin during pregnancy (Jones et al., 1995, Trans. Med. 5:171). Furthermore, with respect to the design of recombinant Rh(D)-immune globulin for use in Rh(D)-negative patients, it may not be necessary to formulate cocktails of monoclonal antibodies containing multiple Rh(D) epitope specificities.
Sequence Data
Genbank accession numbers for anti-Rh(D) heavy chains are as follows: B01, AF044419; C01, AF044420; C03, AF044421; C04, AF044422; C05, AF044423; C08, AF044424; C10, AF044425; D01, AF044426; D03, AF044427; D04, AF044428; D05, AF044429; D07, AF044430; D08, AF044431; D09, AF044432; D10, AF044433; D11, AF044434; D12, AF044435; D13, AF044436; D14, AF044437; D15, AF044438; D16, AF044439; D17, AF044440; D18, AF044441; D20, AF044442; D30, AF044443; D31, AF044444; E01, AF044445; E03, AF044446.
Genbank accession numbers for anti-Rh(D) κ light chains are as follows: F01, AF044447; G01, AF044448; H01, AF044449; I01, AF044450; I02, AF044451; I03, AF044452; I04, AF044453; I05, AF044454; I06, AF044455; I07, AF044456; I08, AF044457; I09, AF044458; I10, AF044459; I11, AF044460; I12, AF044461; I13, AF044462; I15, AF044463; I16, AF044464.
Genbank accession numbers for anti-Rh(D) λ light chains are as follows: J01, AF044465; J02, AF044466; J04, AF044467; J05, AF044468; K01, AF044469; K02, AF044470; K03, AF044471; L01, AF044472; L03, AF044473; L04, AF044474; L05, AF044475; M01, AF044476; M02, AF044477; M03, AF044478; N01, AF044479; N02, AF044480; O01, AF044481; O02, AF044482; O03, AF044483; P01, AF044484; Q01, AF044485; R01, AF044486; S01, AF044487.
Amino Acid Sequences of Anti-Rh(D) Heavy and Light Chains
The amino acid sequences of various anti-Rh(D) chains are represented using single letter amino acid codes, as described herein.
The amino acid sequence of the anti-Rh(D) chain B01 is
The amino acid sequence of the anti-Rh(D) chain C01 is
The amino acid sequence of the anti-Rh(D) chain C03 is
The amino acid sequence of the anti-Rh(D) chain C04 is
The amino acid sequence of the anti-Rh(D) chain C05 is
The amino acid sequence of the anti-Rh(D) chain C08 is
The amino acid sequence of the anti-Rh(D) chain C10 is
The amino acid sequence of the anti-Rh(D) chain D01 is
The amino acid sequence of the anti-Rh(D) chain D03 is
The amino acid sequence of the anti-Rh(D) chain D04 is
The amino acid sequence of the anti-Rh(D) chain D05 is
The amino acid sequence of the anti-Rh(D) chain D07 is
The amino acid sequence of the anti-Rh(D) chain D08 is
The amino acid sequence of the anti-Rh(D) chain D09 is
The amino acid sequence of the anti-Rh(D) chain D10 is
The amino acid sequence of the anti-Rh(D) chain D11 is
The amino acid sequence of the anti-Rh(D) chain D12 is
The amino acid sequence of the anti-Rh(D) chain D13 is
The amino acid sequence of the anti-Rh(D) chain D14 is
The amino acid sequence of the anti-Rh(D) chain D15 is
The amino acid sequence of the anti-Rh(D) chain D16 is
The amino acid sequence of the anti-Rh(D) chain D17 is
The amino acid sequence of the anti-Rh(D) chain D18 is
The amino acid sequence of the anti-Rh(D) chain D20 is
The amino acid sequence of the anti-Rh(D) chain D30 is
The amino acid sequence of the anti-Rh(D) chain D31 is
The amino acid sequence of the anti-Rh(D) chain E01 is
The amino acid sequence of the anti-Rh(D) chain E03 is
The amino acid sequence of the anti-Rh(D) chain F01 is
The amino acid sequence of the anti-Rh(D) chain G01 is
The amino acid sequence of the anti-Rh(D) chain H01 is
The amino acid sequence of the anti-Rh(D) chain I01 is
The amino acid sequence of the anti-Rh(D) chain I02 is
The amino acid sequence of the anti-Rh(D) chain I03 is
The amino acid sequence of the anti-Rh(D) chain I04 is
The amino acid sequence of the anti-Rh(D) chain I05 is
The amino acid sequence of the anti-Rh(D) chain I06 is
The amino acid sequence of the anti-Rh(D) chain I07 is
The amino acid sequence of the anti-Rh(D) chain I08 is
The amino acid sequence of the anti-Rh(D) chain I09 is
The amino acid sequence of the anti-Rh(D) chain I10 is
The amino acid sequence of the anti-Rh(D) chain I11 is
The amino acid sequence of the anti-Rh(D) chain I12 is
The amino acid sequence of the anti-Rh(D) chain I13 is
The amino acid sequence of the anti-Rh(D) chain I15 is
The amino acid sequence of the anti-Rh(D) chain I16 is
The amino acid sequence of the anti-Rh(D) chain J01 is
The amino acid sequence of the anti-Rh(D) chain J02 is
The amino acid sequence of the anti-Rh(D) chain J04 is
The amino acid sequence of the anti-Rh(D) chain J05 is
The amino acid sequence of the anti-Rh(D) chain K01 is
The amino acid sequence of the anti-Rh(D) chain K02 is
The amino acid sequence of the anti-Rh(D) chain K03 is
The amino acid sequence of the anti-Rh(D) chain L01 is
The amino acid sequence of the anti-Rh(D) chain L03 is
The amino acid sequence of the anti-Rh(D) chain L04 is
The amino acid sequence of the anti-Rh(D) chain L05 is
The amino acid sequence of the anti-Rh(D) chain M01 is
The amino acid sequence of the anti-Rh(D) chain M02 is
The amino acid sequence of the anti-Rh(D) chain M03 is
The amino acid sequence of the anti-Rh(D) chain N01 is
The amino acid sequence of the anti-Rh(D) chain N02 is
The amino acid sequence of the anti-Rh(D) chain O01 is
The amino acid sequence of the anti-Rh(D) chain O02 is
The amino acid sequence of the anti-Rh(D) chain O03 is
The amino acid sequence of the anti-Rh(D) chain P01 is
The amino acid sequence of the anti-Rh(D) chain Q01 is
The amino acid sequence of the anti-Rh(D) chain R01 is
The amino acid sequence of the anti-Rh(D) chain S01 is
Nucleotide Sequences of Anti-Rh(D) Heavy and Light Chains
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain B01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C04 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C05 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C08is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain C10 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D04 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D05 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D07 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D08 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D09 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D10 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D11 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D12 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D13 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D14 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D15 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D16 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D17 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D18 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D20 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D30 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain D31 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain E01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain E03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain F01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain G01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain H01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I04 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I05 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I06 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I07 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I08 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I09 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I10 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I11 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I12 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I13 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I15 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain I16 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain J01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain J02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain J04 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain J05 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain K01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain K02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain K03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain L01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain L03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain L04 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain L05 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain M01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain M02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain M03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain N01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain N02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain O01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain O02 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain O03 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain P01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain Q01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain R01 is
The nucleotide sequence of the portion of the clone encoding the anti-Rh(D) chain S01 is
In view of the results obtained in Examples 1 and 2 herein, heavy and light chains of antibodies of various Rh(D) epitope specificities were randomly recombined in order to generate anti-Rh(D) antibodies having additional patterns of reactivity with Rh(D) variant cells. Using this approach, plasmid DNA obtained from the Fab/phage display libraries described in panning rounds 2 and 3 of Example 1 was randomly recombined to generate a “shuffled” Fab/phage display library. When the Rh(D) specificity of antibodies of this “shuffled” library was determine, it was found that many of these antibodies exhibited novel epitope specificity. Significantly, antibody clones having novel Rh(D) epitope specificity were identified, including clones which bind to wild type and certain partial D type red blood cells but which do not bind to D category III red blood cells. The experiments described in this Example therefore demonstrate that the methods described in this specification may be used to generate antibody clones useful for diagnostic and therapeutic applications in humans.
The materials and methods used in the experiments described in this Example are now described.
Creation of Shuffled Fab/Phage Display Library
Two microgram aliquots of DNA obtained from libraries LP2, LP3, KP2, and KP3 (described herein in Example 1) were digested using the restriction endonucleases SpeI and XhoI (15 and 60 units, respectively) in order to dissociate DNA segments encoding individual (full length) heavy chains from library plasmids encoding individual (full length) light chains. Endonuclease/DNA mixtures were incubated overnight at 37° C. After the restriction endonucleases were removed using standard phenol/chloroform and chloroform extraction techniques, the DNA was precipitated using ethanol.
Equivalent amounts of DNA from each of the four libraries (500 nanograms total) were mixed, and then the heavy chain-encoding DNA fragments were re-ligated into the library plasmids encoding individual light chains. This ligation was performed overnight at 20° C. in the presence of 3.5 units of T4 DNA ligase in a total reaction volume of 70 microliters. This treatment generated re-ligated library plasmids encoding a light chain and a heavy chain, wherein the light chain and the heavy chain were not necessarily encoded by a single plasmid in the original library DNA. For this reason, the library of re-ligated plasmids was designated a “shuffled” library.
Three microliters of shuffled library suspension were mixed with an aliquot of XL1-Blue electrocompetent cells (obtained from Stratagene, La Jolla, Calif.), and the cells were electroporated according to standard methods. Electroporated cells were cultured on plates containing Luria broth comprising 100 micrograms per milliliter carbenicillin.
Anti-Rh(D) Specificity of “Shuffled” Library Antibodies
Fifty-six randomly chosen colonies were selected, and monoclonal Fab/phage preparations were separately produced from each of these individual colonies, using the methods described herein in Example 1. Rh(D) specificity was determined by indirect agglutination using anti-M13 antibody, as described herein in Examples 1 and 2. Plasmid DNA was separately prepared from each of the Fab/phage preparations which exhibited Rh(D) specificity, and the DNA sequences encoding the heavy and light chains expressed by each preparation were determined as described herein.
The results of the experiments presented in this Example are now described.
Anti-Rh(D) Specificity of “Shuffled” Library Antibodies
Of the 56 randomly-chosen “shuffled” library clones, 34 (61%) demonstrated specificity for Rh(D). The Rh(D) epitope specificity, the agglutination pattern, and the heavy and light chain sequences of these 34 clones are listed in Table 4. Of these 34 clones, 19 exhibited specificity for previously-described Rh(D) epitopes (e.g. epD 1, epD 2, epD 6/7, and epD X), and one bound too weakly to wild-type Rh(D)-positive red blood cells to characterize is epitope specificity (i.e. clone SH44). However, 14 of the clones identified in Table 4 exhibited novel Rh(D) epitope specificity. Some of these 14 antibody clones comprised a heavy chain, a light chain, or both, that were identified herein in Examples 1 or 2. However, half (17/34) of the heavy chain sequences and about 80% (28/34) of the light chain sequences had not been identified in Examples 1 or 2.
The Rh(D)-specific antibody clones isolated from the “shuffled” library are useful for characterizing and classifying patient red blood cells that express variant forms of the Rh(D) antigen. Of particular interest are clones SH18, SH20, and SH46. These three clones agglutinate wild type red blood cells and certain partial D-type red blood cells, but do not agglutinate D category III red blood cells (a.k.a. partial Rh(D)III cells). It is believed that all previously-characterized human monoclonal anti-Rh(D) antibodies agglutinate D category III red blood cells. Therefore these three clones are particularly useful for differentiating D category III red blood cells from other types of red blood cells.
From a clinical perspective, it has heretofore only been possible to retrospectively identify D category III red blood cells in a patient after they have been erroneously presumed to have wild-type Rh(D)-positive cells. For example, transfusion of an individual having D category III red blood cells with wild-type Rh(D) cells induces production of anti-Rh(D) alloantibodies in the individual. Previously, the presence of D category III red blood cells in patients could only be determined by the production of such anti-Rh(D) alloantibodies in a transfusion recipient who does not naturally harbor D category III red blood cells. Although providing transfused blood comprising D category III red blood cells to a patient who does not naturally harbor such cells will not necessarily cause immediate harm to the patient, the patient thereby becomes alloimmunized against D category III red blood cells. Such alloimmunized individuals may develop complications including hemolytic transfusion reactions or hemolytic disease of the newborn.
Amino Acid Sequences of Anti-Rh(D) Heavy and Light Chains
The amino acid sequences of various anti-Rh(D) antibody chains were as follows, and are represented using single letter amino acid codes.
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH10 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH16 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH17 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH18 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH20 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH24 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH25
The amino acid sequence of the heavy chain of each of anti-Rh(D) antibody clones SH28, SH50, and SH53 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH32 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH37 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH39 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH44 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH47 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH54 is
The amino acid sequence of the heavy chain of anti-Rh(D) antibody clone SH56 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH8 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH12 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH13 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH14 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH16 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH18 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH20 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH21 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH24 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH26 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH28 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH30 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH32 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH34 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH36 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH39 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH41 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH44 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH46 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH47 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH48 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH49 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH50 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH51 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH52 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH54 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH55 is
The amino acid sequence of the light chain of anti-Rh(D) antibody clone SH56 is
Nucleotide Sequences of Anti-Rh(D) Heavy and Light Chains
The nucleotide sequences encoding various anti-Rh(D) antibody clone chains were as follows.
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH10 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH16 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH17 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH18 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH20 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH24 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH25 is
The nucleotide sequence encoding the heavy chain of each of anti-Rh(D) antibody clones SH28, SH50, and SH53 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH32 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH37 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH39 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH44 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH47 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH54 is
The nucleotide sequence encoding the heavy chain of anti-Rh(D) antibody clone SH56 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH8 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH12 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH13 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH14 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH16 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH18 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH20 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH21 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH24 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH26 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH28 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH30 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH32 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH34 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH36 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH39 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH41 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH44 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH46 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH47 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH48 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH49 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH50 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH51 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH52 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH54 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH55 is
The nucleotide sequence encoding the light chain of anti-Rh(D) antibody clone SH56 is
The disclosures of each and every patent, patent application and publication cited herein are hereby incorporated herein by reference in their entirety.
While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.
This application is a divisional of U.S. application Ser. No. 09/240,274, filed Jan. 29, 1999, now issued as U.S. Pat. No. 6,255,455, which in turn is a continuation-in-part of prior U.S. application Ser. No. 08/884,045, filed Jun. 27, 1997 (now issued U.S. Pat. No. 5,876,925), which in turn claims priority under 35 U.S.C. §119(e) to provisional U.S. Application No. 60/081,380, filed Apr. 10, 1998 and to provisional U.S. Application No. 60/028,550, filed Oct. 11, 1996, all of which are incorporated by reference herein as if set forth in their entirety.
This invention was supported in part by a grant from the U.S. Government (NIH Grant No. P50-HL54516) and the U.S. Government may therefore have certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5876925 | Siegel | Mar 1999 | A |
| Number | Date | Country |
|---|---|---|
| WO 9407922 | Apr 1994 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20030040605 A1 | Feb 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60081380 | Apr 1998 | US | |
| 60028550 | Oct 1996 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09240274 | Jan 1999 | US |
| Child | 09848798 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 08884045 | Jun 1997 | US |
| Child | 09240274 | US |
